![PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c00c798d130ef4c229a76e469d1c8e224ebc765b/4-Table5-1.png "PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar")
PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar
Health-related quality of life in the ENDEAVOR study: carfilzomib- dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma | Blood Cancer Journal
Recommendations for MM front-line therapy. ASCT = autologous stem cell... | Download Scientific Diagram
![PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2f0ca3b1a7ecfca0a8a6fce95c955879f5ec3e35/7-Table2-1.png "PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar")
PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised ...
British Journal of Haematology | Wiley Online Library
British Journal of Haematology | Wiley Online Library
Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial | Bone Marrow Transplantation
Treatment indications of multiple myeloma VTD : Bortezomib -Thalidomide... | Download Scientific Diagram
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma | Published in Journal of Health Economics and Outcomes Research
Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR | Leukemia
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse - ScienceDirect
Lenalidomide, Bortezomib, and Dexamethasone Plus ASCT Delays Progression in Myeloma
BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma | 2 Minute Medicine
![PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c00c798d130ef4c229a76e469d1c8e224ebc765b/3-Table2-1.png "PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar")
PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar
Bortezomib, thalidomide and dexamethasone protocol (VTD). | Download Scientific Diagram
Selinexor combined with bortezomib + dexamethasone: the BOSTON trial
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
